BR9407720A - Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto - Google Patents

Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto

Info

Publication number
BR9407720A
BR9407720A BR9407720A BR9407720A BR9407720A BR 9407720 A BR9407720 A BR 9407720A BR 9407720 A BR9407720 A BR 9407720A BR 9407720 A BR9407720 A BR 9407720A BR 9407720 A BR9407720 A BR 9407720A
Authority
BR
Brazil
Prior art keywords
compound
diseases
administration
prevention
treatment
Prior art date
Application number
BR9407720A
Other languages
English (en)
Inventor
Mark Goulet
Helen M Organ
William H Parsons
Peter J Sinclair
Frederick Wong
Matthew J Wyvratt
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9407720A publication Critical patent/BR9407720A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Color Printing (AREA)
BR9407720A 1993-10-04 1994-09-30 Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto BR9407720A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/132,072 US5565560A (en) 1991-05-13 1993-10-04 O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
PCT/US1994/011114 WO1995009857A1 (en) 1993-10-04 1994-09-30 O-aryl, o-alkyl, o-alkenyl and o-alkynyl-macrolides having immunosuppressive activity

Publications (1)

Publication Number Publication Date
BR9407720A true BR9407720A (pt) 1997-03-04

Family

ID=22452330

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407720A BR9407720A (pt) 1993-10-04 1994-09-30 Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto

Country Status (18)

Country Link
US (2) US5565560A (pt)
EP (1) EP0722448A4 (pt)
JP (1) JPH09503507A (pt)
KR (1) KR960704896A (pt)
CN (1) CN1137275A (pt)
AU (1) AU690157B2 (pt)
BG (1) BG100474A (pt)
BR (1) BR9407720A (pt)
CA (1) CA2172124A1 (pt)
CZ (1) CZ99396A3 (pt)
FI (1) FI961496A0 (pt)
HU (1) HUT74591A (pt)
LV (1) LV11547B (pt)
NO (1) NO961345L (pt)
NZ (1) NZ275203A (pt)
PL (1) PL313870A1 (pt)
SK (1) SK43096A3 (pt)
WO (1) WO1995009857A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563172A (en) * 1991-09-05 1996-10-08 Abbott Laboratories Macrocyclic amide and urea immunomodulators
EP0689545A4 (en) * 1993-03-17 1996-04-24 Abbott Lab IMMUNOREGULATORS WITH MACROCYCLIC AMIDE AND UREA
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US6413967B1 (en) * 1995-03-30 2002-07-02 The University Of Virginia Patents Foundation Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy
US6271244B1 (en) 1998-06-03 2001-08-07 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US6274602B1 (en) 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6187796B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Sulfone hair growth compositions and uses
US20010049381A1 (en) * 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6429215B1 (en) 1998-06-03 2002-08-06 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
EP1085853A1 (en) 1998-06-03 2001-03-28 GPI NIL Holdings, Inc. Heterocyclic ester and amide hair growth compositions and uses
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
AU2007237187B2 (en) * 2002-07-16 2010-08-05 Biotica Technology Limited Production of polyketides
PT1539157E (pt) * 2002-09-18 2013-10-04 Univ Pennsylvania Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
DE10250870A1 (de) * 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
CN1882338A (zh) * 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
AU2005326322B2 (en) * 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
JP2008528491A (ja) 2005-01-20 2008-07-31 アレイ バイオファーマ、インコーポレイテッド 免疫調節性障害および呼吸器の疾患の処置のための大環状アナログ
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2564194T3 (es) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Formulaciones líquidas para el tratamiento de enfermedades o dolencias
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) * 2007-03-02 2010-06-17 Fong Peter M Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US8445002B2 (en) 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
JP2016516754A (ja) 2013-04-03 2016-06-09 アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｌｅｒｔｅｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 新規のナノ粒子組成物
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
WO2015117024A1 (en) 2014-01-31 2015-08-06 Mayo Foundation For Medical Education And Research Novel therapeutics for the treatment of glaucoma
CN115768419A (zh) * 2020-02-07 2023-03-07 奎拉里斯生物公司 用于色满卡林前药治疗的改进方法和组合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
DK175235B1 (da) * 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
AU630866B2 (en) * 1987-12-09 1992-11-12 Fisons Plc Macrocyclic compounds
EP0349061B1 (en) * 1988-06-29 1995-03-29 Merck & Co. Inc. Immunosuppressant agent
US4981792A (en) * 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
EP0353678B1 (en) * 1988-08-01 1995-12-13 Fujisawa Pharmaceutical Co., Ltd. FR-901154 and FR-901155 substances, a process for their production
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
AU630122B2 (en) * 1988-11-15 1992-10-22 Abbott Laboratories N-arylation of isatins
EP0388152B1 (en) * 1989-03-15 1994-10-12 Merck & Co. Inc. Process for producing an immunosuppressant agent (demethimmunomycin) using a mutant strain of a microorganism
US4987139A (en) * 1989-05-05 1991-01-22 Merck & Co., Inc. FK-520 microbial transformation product
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
KR920700212A (ko) * 1989-06-14 1992-02-19 쟝 크라머·한스 루돌프 하우스 헤테로원자-함유 트리사이클릭 화합물
AU6286690A (en) * 1989-08-18 1991-04-03 Fisons Plc Macrocyclic compounds
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
JPH05504956A (ja) * 1990-03-12 1993-07-29 藤沢薬品工業株式会社 トリシクロ化合物
JPH05505798A (ja) * 1990-03-13 1993-08-26 フアイソンズ・ピーエルシー 免疫抑制マクロ環状化合物
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
CA2044846A1 (en) * 1990-06-25 1991-12-26 Thomas R. Beattie Antagonists of immunosuppressive macrolides
GB2245891A (en) * 1990-07-09 1992-01-15 Fujisawa Pharmaceutical Co Tricyclo compounds
WO1992003441A1 (en) * 1990-08-18 1992-03-05 Fisons Plc Macrocyclic compounds
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity

Also Published As

Publication number Publication date
CA2172124A1 (en) 1995-04-13
NO961345D0 (no) 1996-04-02
NZ275203A (en) 1998-01-26
LV11547A (lv) 1996-10-20
AU8073794A (en) 1995-05-01
US5532248A (en) 1996-07-02
LV11547B (en) 1997-02-20
BG100474A (en) 1996-12-31
CN1137275A (zh) 1996-12-04
SK43096A3 (en) 1996-10-02
US5565560A (en) 1996-10-15
NO961345L (no) 1996-06-03
HU9600870D0 (en) 1996-06-28
KR960704896A (ko) 1996-10-09
JPH09503507A (ja) 1997-04-08
EP0722448A1 (en) 1996-07-24
AU690157B2 (en) 1998-04-23
WO1995009857A1 (en) 1995-04-13
PL313870A1 (en) 1996-07-22
FI961496A (fi) 1996-04-03
EP0722448A4 (en) 1998-04-29
FI961496A0 (fi) 1996-04-03
CZ99396A3 (en) 1996-09-11
HUT74591A (en) 1997-01-28

Similar Documents

Publication Publication Date Title
BR9407720A (pt) Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto
BR9406128A (pt) Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
BR9404203A (pt) Compostos, processo para a preparação dos mesmos, medicamento, uso dos ditos compostos e processo de tratamento ou prevenção de distúrbios nervosos centrais
PT98944A (pt) Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes
BR9707616A (pt) Composto composiç o farmacéutica utilização de um composto e processo para a preparação de um composto para o tratamento ou profilaxia de distúrbios de deficiéncia intelectual ou profilaxia da doença de parkinson doença de huntington síndrome de tourette esclerose amiotrófica lateral ou distúrbios neurodegenerativos
BR9602542A (pt) Composto método para o tratamento de uma doença dependente da fosforilase de glicogénio composição farmacéutica e processo para a preparação de um composto
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
BR9608405A (pt) Composto composi-Æo farmaceutica e processo para tratar um paciente que sofre de um distÚrbio fisiolÄgico
BR9503812A (pt) Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
BR9507656A (pt) Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
ES2160124T3 (es) Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades.
IT9048260A0 (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
BR9707003A (pt) Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto
BR9509257A (pt) Modafinil possuindo tamanho de partícula definido
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
IT9048261A0 (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
LV11666A (lv) Farmaceitiskie preparati un medikamenti endotelialo traucejumu noversanai un arstesanai
BR9506581A (pt) Composto composição farmacêutica uso do composto processo para a profilaxia ou tratamento de uma condição clínica em um manífero por exemplo um humano e para a preparação de um composto e composto intermediário
BR9609798A (pt) Composição fungicida sinérgica processo para o controle de fungos fitopatogênicos processo para o controle de cura ou prevenção de fungos e produto
BR9708864A (pt) Composto composição farmacêutica e processo para o tratamento ou a prevenção de uma infecção bacteriana em um paciente mamífero

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal